



Management of Anticoagulation in the Peri-procedural Period Application

Free Clinical Decision Support App Helps Clinicians Manage Anticoagulation Medications During Surgery



Management of Anticoagulation in the Peri-Procedural Period

The Challenge

Patients receiving chronic anticoagulant therapy who undergo surgical or invasive medical interventions are at increased risk of bleeding. However, withholding anti-coagulants for these patients increases the risk of clotting due to the underlying conditions for which anticoagulation was originally prescribed. While the medical literature contains expert guidance for the use of anticoagulants during invasive procedures, a simplified reference guide to anticoagulant use that clinicians can quickly refer to when planning these procedures has been lacking.

The Approach

In 2013, IPRO and the New York State (NYS) Anticoagulation Coalition launched the Peri-Procedural Task Force to develop the Management of Anticoagulation in the Peri-Procedural Period (MAPPP) Guide to promote standardized evidence-based prescribing during invasive procedures. Approximately 5,000 printed copies of this guide have been distributed to more than 100 hospitals across NYS.

The MAPPP tool supports CMS's commitment to achieve the National Quality Strategy and the CMS Quality Strategy that support the three-part aim of improving health, improving care, and lowering costs using innovative techniques, by using technology to put critical evidence-based information into the hands of clinicians when they need it.

In 2016, the MAPPP guide content was updated and adapted into a mobile and web-based application (MAPPP app) that permits clinicians to easily determine whether, when, and how to stop and restart the use of warfarin, direct oral anticoagulants, and antiplatelets during elective surgery and other invasive procedures. The app provides individualized patient guidance for management of anticoagulant medications based on patient thromboembolic risk and specific procedural bleeding risk, and is an educational resource for providers.

IPRO has distributed the MAPPP app to care transition communities and members of the NYS Anticoagulation Coalition, and posted the application on the IPRO website. The tool is currently available on the Apple App Store and on Google Play for Androids. The IPRO team has educated physicians and provider staff across NYS on the MAPPP app, supported its integration into clinical decision support (CDS) at selected healthcare systems, and developed a process for incorporating the app into electronic health record CDS across multiple inpatient and outpatient vendor systems.


The supporting evidence for the underlying assessment and medical recommendations provided in the MAPPP app was published in the *Journal of Thrombosis and Hemostasis*.¹

Management of Anticoagulation in the Peri-procedural Period Application

continued

Results/Clinical Outcomes²

- There were 353 new users of the app globally in its first full calendar quarter of use (April–June 2016), primarily in the US (276; 78.18%) and in the project's home state of New York (168; 47.59%).
- App acquisition trended upwards through Q3 2017, accruing 2,866 total global new users, dominated by use in the US (2,013; 70.24%) and New York, in particular (1,067; 37.23%).
- The app was downloaded and used for at least one episode (a user interaction that resulted in the app presenting a recommendation page based on the drug, bleeding risk, and thromboembolic risk selected by the user) in 51 different countries during the measurement period.
- Users completed nearly 10,000 episodes, exceeding 2,000 episodes in each of the most recent calendar quarters.
- Overall, utilization was highest in the US (6,748; 67.73%), and New York in particular (3,618; 36.31%).
- Globally, episodes were spread approximately evenly between new users (4,571; 45.88%) and returning users (5,392; 54.12%).



Sample screenshot of a MAPP App Recommendation

A CMS Special Innovation Project is underway to integrate MAPP decision support into three electronic health record systems using SMART on FHIR technology, with the goal of reducing 30-day post-procedure bleeding, thromboembolic and death events.

IPRO brings policy ideas to life

IPRO helps clients realize better health through its organizational competencies. We

- Support state and federal government agency problem solving
- Foster consensus among varied stakeholders for quality improvement action
- Evaluate and select most appropriate methodologies to investigate clinical quality problems
- Facilitate collaborative provider education and action
- Harness information technology to drive quality improvement
- Build and apply quality measures
- Collect and analyze data on large scale
- Create tools to assess performance

1. Spyropoulos, A.C., et al., Periprocedural Management of Patients on a Vitamin K Antagonist or a Direct Oral Anticoagulant Requiring an Elective Procedure or Surgery. *J Thromb Haemost*, 2016.
 2. Data was extracted from Google Analytics to characterize new users and completed episodes for the period from April 1, 2016, through September 30, 2017.